Kaye, Keith S.
Gupta, Vikas
Mulgirigama, Aruni
Joshi, Ashish V.
Ye, Gang
Scangarella-Oman, Nicole E.
Yu, Kalvin
Mitrani-Gold, Fanny S.
Article History
Received: 15 November 2023
Accepted: 24 January 2024
First Online: 14 February 2024
Declarations
:
: The study was performed using a de-identified limited retrospective dataset that was deemed exempt from patient consent by the New England Institutional Review Board/Human Subjects Research Committee (Wellesley, MA, US). The study was conducted in compliance with Health Insurance Portability and Accountability Act requirements.
: Not applicable.
: KSK declares the following: consulting fees from AbbVie, Allecra, Carb-X, Merck, Shionogi, Spero, and Venatorx; and symposia honoraria from GSK. VG was an employee of, and shareholder in, Becton, Dickinson and Company at the time of the analysis, and the company received funding from GSK to conduct this study. AM is an employee of, and shareholder in, GSK. AVJ is an employee of, and shareholder in, GSK. GY was an employee of Becton, Dickinson and Company, and the company received funding from GSK to conduct this study. NESO is an employee of, and shareholder in, GSK. KY is an employee of, and shareholder in, Becton, Dickinson and Company, and the company received funding from GSK to conduct this study. FSMG is an employee of, and shareholder in, GSK. Some of the material discussed in this manuscript was previously presented at Infectious Diseases Week (IDWeek) 2022; Kaye, et al., presentation 2227, “Prevalence, Regional Distribution, and Trends of Antimicrobial Resistance Among Female Outpatients With Urine <i>Klebsiella pneumoniae</i> Isolates: A Multicenter Evaluation”.